- Home
- SYBX vs PRPH Comparison
SYBX vs PRPH Comparison
Compare SYBX & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- PRPH
- Stock Information
- Founded
- SYBX N/A
- PRPH 1989
- Country
- SYBX United States
- PRPH United States
- Employees
- SYBX N/A
- PRPH N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- PRPH Health Care
- Exchange
- SYBX Nasdaq
- PRPH Nasdaq
- Market Cap
- SYBX 17.0M
- PRPH 15.5M
- IPO Year
- SYBX N/A
- PRPH 1997
- Fundamental
- Price
- SYBX $1.42
- PRPH $0.64
- Analyst Decision
- SYBX Hold
- PRPH Strong Buy
- Analyst Count
- SYBX 3
- PRPH 1
- Target Price
- SYBX $1.00
- PRPH $11.00
- AVG Volume (30 Days)
- SYBX 74.6K
- PRPH 237.1K
- Earning Date
- SYBX 11-12-2024
- PRPH 11-13-2024
- Dividend Yield
- SYBX N/A
- PRPH N/A
- EPS Growth
- SYBX N/A
- PRPH N/A
- EPS
- SYBX N/A
- PRPH N/A
- Revenue
- SYBX $2,777,000.00
- PRPH $12,753,000.00
- Revenue This Year
- SYBX N/A
- PRPH $36.93
- Revenue Next Year
- SYBX N/A
- PRPH $132.05
- P/E Ratio
- SYBX N/A
- PRPH N/A
- Revenue Growth
- SYBX 292.23
- PRPH N/A
- 52 Week Low
- SYBX $1.22
- PRPH $0.61
- 52 Week High
- SYBX $5.12
- PRPH $7.48
- Technical
- Relative Strength Index (RSI)
- SYBX 48.54
- PRPH 27.48
- Support Level
- SYBX $1.36
- PRPH $0.66
- Resistance Level
- SYBX $1.88
- PRPH $0.74
- Average True Range (ATR)
- SYBX 0.09
- PRPH 0.06
- MACD
- SYBX -0.01
- PRPH 0.04
- Stochastic Oscillator
- SYBX 11.54
- PRPH 10.71
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.